RECRUITING Phase 2 ClinicalTrials.gov

Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy

Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • ClinicalTrials.gov ID: NCT07803965

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is an early phase clinical study. Patients who are at high risk of developing severe acute pancreatitis will be screened. Participants will be randomly assigned to receive either SGC001 injection or a placebo injection that contains no active medicine. The study will check how safe and well tolerated SGC001 is, how the body processes this study drug, its biological effects, and whether it may help treat this condition. The study consists of Part A, a dose escalation phase primarily focused on safety and tolerability, and Part B, a dose exploration phase primarily focused on efficacy, both administered as a single add on dose to standard care in patients with predicted severe acute pancreatitis.

Interventions

SGC001 injection (Drug)
Specification:400mg (10mL) per vial Part A: Dosage and Administration:300mg or 600mg, other dosage determined by the safety review committee (SRC) administered as a single intravenous infusion Infusion Duration:60±10minutes Part B: Based on clinical pharmacokinetic, safety and/or efficacy data obtained from the Part A dose escalation phase, the SRC will select 1 or 2 optimal dose cohorts. Infusion Duration:60±10minutes administered as a single intravenous infusion
Placebo (Drug)
Specification: 0mg(10mL)per vial Dosage Administration: 0mg as a single intravenous infusion Infusion Duration:60±10minutes

Eligibility criteria

Inclusion Criteria: 1. Aged 18 to 75 years inclusive, with no restriction on gender 2. Meet the diagnostic criteria for acute pancreatitis (AP) specified in the IAP Guidelines for the Management of Acute Pancreatitis (2025 Revision), i.e., satisfying at least two of the following three criteria: Clinical criterion: Acute epigastric abdominal pain; Biochemical criterion: Elevated pancreatic enzymes (serum lipase or amylase level more than 3 times the upper limit of normal (ULN)); Imaging criterion: Abdominal imaging examination (computed tomography (CT) or ultrasound) demonstrating findings consistent with acute pancreatic inflammation, with or without necrosis. 3. Meet the manifestations of predicted severe acute pancreatitis (AP) Exclusion Criteria: 1. The exact onset time of abdominal pain cannot be accurately determined. 2. History of endoscopic retrograde cholangiopancreatography (ERCP) performed within 7 days prior to screening; 3. Received extracorporeal membrane oxygenation (ECMO) or renal replacement therapy prior to admission; 4. Requirement for emergency surgery, ERCP, ECMO, renal replacement therapy or plasma exchange immediately upon admission; 5. Having a known medical history of severe cardiovascular, respiratory, renal, hepatic, hematological or immune diseases; 6. Subjects with current malignancy or a prior history of malignant tumors, except for basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder tumors or carcinoma in situ of the cervix that have been cured for at least 5 years. 7. Subjects suffering from severe psychiatric disorders, cognitive impairment caused by severe social environmental factors, or any other conditions that the investigator judges may lead to poor protocol compliance or expose the subject to additional safety risks during the trial. 8. Administration of live vaccines within 1 month prior to screening; 9. Female subjects who are pregnant or breastfeeding; female subjects of childbearing potential who have had unprotected sexual intercourse within 1 month prior to screening, or with a positive pregnancy test at screening; subjects (or their partners) who plan to conceive, donate sperm or oocytes throughout the study period and within 6 months after study completion; subjects who refuse to use one or more effective contraceptive methods during the study and for 6 months following the end of the study.

Conditions

Acute Pancreatitis

Locations

West China Hospital, Sichuan University — Chengdu, China
The Affiliated Hospital of Guizhou Medical University — Guizhou, China
Zhejiang Provincial People's Hospital — Hangzhou, China
The Second Affiliated Hospital of Anhui Medical University — Hefei, China
The First Affiliated Hospital of Henan University of Science and Technology — Luoyang, China
The First Affiliated Hospital of Nanchang University — Nanchang, China
General Hospital of the Eastern Theater Command of the Chinese People's Liberation Army — Nanjing, China
Li Huili Hospital, Ningbo Medical Center — Ningbo, China
Shanghai General Hospital — Shanghai, China
General Hospital of Northern Theater Command of the Chinese People's Liberation Army — Shenyang, China
The Second Hospital of Hebei Medical University — Shijiazhuang, China
Renmin Hospital of Wuhan University — Wuhan, China
The First Affiliated Hospital of Xiamen University — Xiamen, China
Zhongshan Hospital, Xiamen University — Xiamen, China
Zibo Central Hospital — Zibo, China

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment